Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571252 | 0.79 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL2917482 | 0.78 | CYP19A1 (1.00) | CYP19A1HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL9382670 | 0.77 | CYP19A1 (0.96) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL17159812 | 0.76 | CYP19A1 (0.80) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL27979676 | 0.75 | HTT (0.48) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL9023539 | 0.72 | CYP19A1 (0.86) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL27779924 | 0.72 | CYP19A1 (0.37) | CYP19A1 | |
| SCHEMBL15688800 | 0.71 | CYP19A1 (0.71) | CYP19A1HDAC1HDAC6STS | |
| SCHEMBL3115446 | 0.70 | CYP19A1 (0.65) | CYP19A1HDAC1HDAC6STSUGT1A4 | |
| SCHEMBL10066953 | 0.70 | CYP19A1 (0.65) | CYP19A1HDAC1HDAC6STSUGT1A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115417859-B | Synthesis method of rizatriptan benzoate | 陕西师范大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-102123991-A | 2-arylaminoquinazolines for the treatment of proliferative diseases | NOVARTIS AG | 2011-07-13 | — | — | CN | disclosed |
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2236505-A1 | Acylated aminopyridines and pyridazines as insecticides | Bayer CropScience AG (DE) | 2010-10-06 | — | — | EP | disclosed |
| CN-101652352-A | Quinazolines for PDK1 inhibition | NOVARTIS VACCINES & DIAGNOSTIC | 2010-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | AAAS, DDT, QDPR | CYP19A1 726/4885HDAC1 944/4885HDAC6 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.